⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16287988 | 0.73 | — | — | |
| SCHEMBL28829234 | 0.69 | CYP11B2 (0.31) | — | |
| SCHEMBL12471356 | 0.63 | — | — | |
| SCHEMBL448950 | 0.62 | — | — | |
| SCHEMBL4465626 | 0.62 | — | — | |
| SCHEMBL387530 | 0.62 | — | — | |
| SCHEMBL1448773 | 0.62 | — | — | |
| SCHEMBL352259 | 0.62 | — | — | |
| SCHEMBL19322528 | 0.60 | KDM4E (0.31) | — | |
| SCHEMBL4917687 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036291-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | claimed |
| WO-2024123967-A1 | SARM1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SENYA PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| CN-118005611-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-05-09 | — | — | US | claimed |
| CN-112292380-B | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer | 因赛特公司 | 2024-04-05 | — | — | CN | claimed |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
| US-20230405008-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | KURA ONCOLOGY, INC. | 2023-12-21 | — | — | US | claimed |
| CN-117157291-A | Heterocyclic derivatives as P2X7 receptor antagonists | 布雷耶疗法有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | claimed |
| EP-4262975-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Breye Therapeutics ApS (DK) | 2023-10-25 | — | — | EP | claimed |
| WO-2008025735-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | claimed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| EP-1646638-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2004108745-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| WO-2004108746-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-6774115-B1 | BACTERICIDES | ENANTA PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | claimed |
| US-6716820-B1 | BACTERICIDES | ENANTA PHARMACEUTICALS, INC. | 2004-04-06 | — | — | US | claimed |
| EP-0199968-B1 | THIAZOLE DERIVATIVES | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-02-28 | — | — | EP | claimed |
| US-4804668-A | CARDIOTONIC AGENTS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-02-14 | — | — | US | claimed |
| EP-0199968-A1 | Thiazole derivatives | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-11-05 | — | — | EP | claimed |